-+ 0.00%
-+ 0.00%
-+ 0.00%

BRAINSTORM CELL THERAPEUTICS SUBMITS IND AMENDMENT TO FDA, PAVING THE WAY FOR PHASE 3B TRIAL OF NUROWN® IN ALS

Reuters·04/10/2025 11:30:04

Please log in to view news